Results 71 to 80 of about 12,335 (206)

pH/ROS‐Responsive Injectable Hydrogel Co‐Loaded with B7‐H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy

Advanced Science, EarlyView.
A pH/ROS‐dual‐responsive injectable hydrogel, formed by dynamic boronic ester and Schiff base crosslinking, co‐delivers enoblituzumab (B7‐H3 blocker) and Cl‐amidine (NETs suppressor). Via localized intratumoral delivery, it synergistically reprograms the immunosuppressive tumor microenvironment, overcomes T cell infiltration barriers, restores ...
Huan Li, Yun Li, Yating Hu, Yanbing Yao, Yaodong He, Jing Li, Jiaqi Tang, Zhenyan Zhao, Yan Wang, Yulun He, Xiaolong Zhang, Xinjie Yang, Jianhua Wei   +12 more
wiley   +1 more source

B7-H3: An Attractive Target for Antibody-based Immunotherapy

Clinical Cancer Research, 2021
Abstract The recent impressive clinical responses to antibody-based immunotherapy have prompted the identification of clinically relevant tumor antigens that can serve as targets in solid tumors. Among them, B7-H3, a member of the B7 ligand family, represents an attractive target for antibody-based immunotherapy, it is overexpressed ...
Filippos Kontos, Theodoros Michelakos, Tomohiro Kurokawa, Ananthan Sadagopan, Joseph H. Schwab, Cristina R. Ferrone, Soldano Ferrone   +6 more
openaire   +3 more sources

N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer

iScience
Summary: B7-H3 is a common oncogene found in various cancer types. However, the molecular mechanisms underlying abnormal B7-H3 expression and colorectal cancer (CRC) progression need to be extensively explored.
Rui Chen, Fei Su, Tao Zhang, Dongjin Wu, Jingru Yang, Quanlin Guan, Chen Chai   +6 more
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

B7-H3 Promotes Prostate Cancer Progression in Mice by Antagonizing Myeloid-Derived Suppressor Cell Apoptosis

Technology in Cancer Research & Treatment, 2020
Background: B7-H3 is an important immunomodulatory molecule, and clinical studies have confirmed that its expression level is closely correlated with prostate cancer prognosis. However, the mechanism of its biological action is unclear.
Yunfen Zhou MD, Guangbo Zhang PhD, Weijie Zhang PhD, Xuedong Wei PhD, Jianquan Hou PhD, Yuhua Huang PhD   +5 more
doaj   +1 more source

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Journal of Hematology & Oncology, 2022
Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been ...
Binghao Zhao, Huanzhang Li, Yu Xia, Yaning Wang, Yuekun Wang, Yixin Shi, Hao Xing, Tian Qu, Yu Wang, Wenbin Ma   +9 more
doaj   +1 more source

Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting [PDF]

PURPOSE: Uveal melanoma (UM) is the most common intraocular malignant tumor. Despite successful treatment of the primary tumor, about 50% of patients will recur with systemic diseases for which there are no effective treatment strategies.
Arya, Shahrzad, Boland, Genevieve M., Cattaneo, Giulia, Ferrone, Cristina R., Gelmi, Maria C., Haq, Rizwan, Jager, Martine J., Jenkins, Russell W., Jia, Jingyu, Ksander, Bruce R., Maggs, Luke, Ryeom, Sandra, Sun, Yi, Ventin, Marco, Verdijk, Robert M., Wang, Xinhui   +15 more
core   +3 more sources

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells [PDF]

, 2019
The high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an attractive target for immunotherapy. We generated chimeric antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR-Ts) and found that B7-H3.CAR-Ts
Ahn, S., Chen, Y., Dotti, G., Du, H., Ferrone, C.R., Ferrone, S., Greene, K., Herrera, S.G., Hirabayashi, K., Kren, N.P., Liu, R., Ma, X., Michaud, D., Mirlekar, B., Montgomery, S.A., Pylayeva-Gupta, Y., Savoldo, B., Sun, C., Tiruthani, K., Wang, X., Xu, Y., Yeh, J.J.   +21 more
core   +2 more sources

Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia [PDF]

, 2021
Purpose: The development of safe and effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant expression of most AML-associated surface antigens on normal myeloid progenitors ...
Ahn, S., Dotti, G., Du, H., Ferrone, S., Li, G., Lichtman, E.I., Savoldo, B., Shou, P., Song, F., Su, L., Suzuki, K.   +10 more
core   +2 more sources

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Advanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu, Ling Peng, Lu Lu, Huiyi Feng, Yan Zhong, Guisen Tan, Zhicheng Zhang, Liqin Huang, Chao Su, Ying Xue, Shuo Song, Wenxia Fan, Wei Wang, Fan Zou   +24 more
wiley   +1 more source